(S1 (S (S (NP (NN Angiogenesis) (NNS inhibitors)) (: :) (NP (NP (JJ current) (NNS strategies)) (CC and) (NP (JJ future) (NNS prospects)))) (. .)))
(S1 (S (S (NP (NN Angiogenesis)) (VP (VBZ has) (VP (VBN become) (NP (NP (DT an) (JJ attractive) (NN target)) (PP (IN for) (NP (NN drug) (NN therapy)))) (PP (IN because) (IN of) (NP (NP (PRP$ its) (JJ key) (NN role)) (PP (IN in) (NP (NN tumor) (NN growth)))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ extensive) (NN array)) (PP (IN of) (NP (NNS compounds)))) (VP (VBZ is) (ADVP (RB currently)) (PP (IN in) (NP (JJ preclinical) (NN development))) (, ,) (PP (IN with) (S (NP (JJ many)) (VP (VP (ADVP (RB now)) (VBG entering) (NP (DT the) (NN clinic))) (CC and/or) (VP (VBG achieving) (NP (NN approval)) (PP (IN from) (NP (DT the) (NP (PRP US)) (NP (NP (NN Food)) (CC and) (NP (NN Drug)) (NP (NN Administration))))))))))) (. .)))
(S1 (S (S (NP (JJ Several) (JJ regulatory) (CC and) (NN signaling) (NNS molecules)) (VP (VBG governing) (NP (NN angiogenesis))) (VP (VBP are) (PP (IN of) (NP (NN interest))) (, ,) (PP (VBG including) (NP (NP (NP (NP (NN growth) (NNS factors)) (PRN (-LRB- -LRB-) (NP (NN eg)) (, ,) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (, ,) (NP (JJ platelet-derived) (NN growth) (NN factor)) (, ,) (NP (NN fibroblast) (NN growth) (NN factor)) (, ,) (CC and) (NP (JJ epidermal) (NN growth) (NN factor))) (-RRB- -RRB-))) (, ,) (NP (NN receptor) (NN tyrosine) (NNS kinases)) (, ,) (CC and) (NP (NN transcription) (NNS factors))) (PP (JJ such) (IN as) (NP (NP (ADJP (NN hypoxia) (JJ inducible)) (NN factor)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS molecules)) (VP (VBN involved) (PP (IN in) (NP (NP (NP (NP (JJ mitogen-activated) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN MAPK)) (-RRB- -RRB-))) (CC and) (NP (NP (NN phosphoinositide) (NN 3-kinase)) (PRN (-LRB- -LRB-) (NP (NN PI3K)) (-RRB- -RRB-)))) (NN signaling))))))))))) (. .)))
(S1 (S (S (S (NP (JJ Pharmacologic) (NNS agents)) (VP (VBP have) (VP (VBN been) (VP (VBN identified) (SBAR (WHNP (WDT that)) (S (VP (VBP target) (NP (DT these) (NNS pathways))))))))) (, ,) (CC yet) (S (PP (IN for) (NP (NP (DT some) (NNS agents)) (PRN (-LRB- -LRB-) (NP (ADVP (RB notably)) (NP (NN thalidomide))) (-RRB- -RRB-)))) (, ,) (NP (NP (DT an) (NN understanding)) (PP (IN of) (NP (NP (DT the) (JJ specific) (NNS mechanisms)) (PP (IN of) (NP (NN antitumor) (NN action)))))) (VP (VBZ has) (VP (VBD proved) (ADJP (JJ elusive)))))) (. .)))
(S1 (S (S (NP (DT The) (JJ following) (NN review)) (VP (VBZ describes) (NP (NP (NP (JJ key) (JJ molecular) (NNS mechanisms)) (CC and) (NP (JJ novel) (NNS therapies))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (PP (IN on) (NP (NP (DT the) (NN horizon)) (PP (IN for) (NP (JJ antiangiogenic) (NN tumor) (NN therapy))))))))))) (. .)))
